Primary navigation

    Lynparza

    Drug - Lynparza™ (olaprarib capsules) [AstraZeneca]

    November 2015

    Therapeutic area - Oncology

    Approved criteria

    The patient must meet all of the following criteria:

    • Has advanced ovarian cancer 
    • Has deleterious or suspected deleterious germline BRCA mutations as detected by an FDA approved test 
    • Has a history of failure to, contraindication to or intolerance to three or more prior lines of chemotherapy

    Quantity limits

    Maximum of 544 capsules per 34 days

    Background information

    Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top